[en] Assessment of telomere length (TL) in peripheral blood leukocytes is part of the diagnostic algorithm applied to patients with acquired bone marrow failure syndromes (BMFSs) and dyskeratosis congenita (DKC). Monochrome multiplex-quantitative polymerase chain reaction (MM-qPCR) and fluorescence in situ hybridization (flow-FISH) are methodologies available for TL screening. Dependent on TL expressed in relation to percentiles of healthy controls, further genetic testing for inherited mutations in telomere maintenance genes is recommended. However, the correct threshold to trigger this genetic workup is still under debate. Here, we prospectively compared MM-qPCR and flow-FISH regarding their capacity for accurate identification of DKC patients. All patients (n = 105) underwent genetic testing by next-generation sequencing and in 16 patients, mutations in DKC-relevant genes were identified. Whole leukocyte TL of patients measured by MM-qPCR was found to be moderately correlated with lymphocyte TL measured by flow-FISH (r(2) = 0.34; P < 0.0001). The sensitivity of both methods was high, but the specificity of MM-qPCR (29%) was significantly lower compared with flow-FISH (58%). These results suggest that MM-qPCR of peripheral blood cells is inferior to flow-FISH for clinical routine screening for suspected DKC in adult patients with BMFS due to lower specificity and a higher rate of false-positive results.
Disciplines :
Hematology
Author, co-author :
Ferreira, Monica S. Ventura
Kirschner, Martin
Halfmeyer, Insa
Estrada, Natalia
Xicoy, Blanca
Isfort, Susanne
Vieri, Margherita
Zamora, Lurdes
Abels, Anne
Bouillon, Anne-Sophie ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'hématologie clinique
Drummond, M.W. et al. 2007. Concise review: telomere biology in normal and leukemic hematopoietic stem cells. Stem Cells 25: 1853–1861.
Blasco, M.A. 2007. Telomere length, stem cells and aging. Nat. Chem. Biol. 3: 640–649.
Martinez, P. & M.A. Blasco. 2011. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat. Rev. Cancer 11: 161–176.
de Lange, T. 2009. How telomeres solve the end-protection problem. Science 326: 948–952.
Blasco, M.A. 2005. Telomeres and human disease: ageing, cancer and beyond. Nat. Rev. Genet. 6: 611–622.
Young, N.S. 2010. Telomere biology and telomere diseases: implications for practice and research. Hematology Am. Soc. Hematol. Educ. Program 2010: 30–35.
Calado, R. & N. Young. 2012. Telomeres in disease. F1000 Med. Rep. 4: 8.
Calado, R.T. & N.S. Young. 2009. Telomere diseases. N. Engl. J. Med. 361: 2353–2365.
Calado, R.T. & N.S. Young. 2008. Telomere maintenance and human bone marrow failure. Blood 111: 4446–4455.
Townsley, D.M., B. Dumitriu & N.S. Young. 2014. Bone marrow failure and the telomeropathies. Blood 124: 2775–2783.
Dokal, I. 2011. Dyskeratosis congenita. Hematology Am. Soc. Hematol. Educ. Program 2011: 480–486.
Kirwan, M. & I. Dokal. 2008. Dyskeratosis congenita: a genetic disorder of many faces. Clin. Genet. 73: 103–112.
Ziegler, P. et al. 2012. Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation. Ann. Hematol. 91: 1115–1120.
Alter, B.P. 2017. Inherited bone marrow failure syndromes: considerations pre- and posttransplant. Blood 130: 2257–2264.
Townsley, D.M. et al. 2016. Danazol treatment for telomere diseases. N. Engl. J. Med. 374: 1922–1931.
Brummendorf, T.H. et al. 2001. Limited telomere shortening in hematopoietic stem cells after transplantation. Ann. N.Y. Acad. Sci. 938: 1–7; discussion 7–8.
Brummendorf, T.H. et al. 2001. Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders. Ann. N.Y. Acad. Sci. 938: 293–303; discussion 303–294.
Alter, B.P. et al. 2015. Telomere length in inherited bone marrow failure syndromes. Haematologica 100: 49–54.
Baerlocher, G.M. et al. 2006. Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nat. Protoc. 1: 2365–2376.
Kirschner, M. et al. 2018. Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita. Leukemia 32: 1762–1767.
Weidner, C.I. et al. 2016. DNA methylation in PRDM8 is indicative for dyskeratosis congenita. Oncotarget 7: 10765–10772.
Beier, F. et al. 2005. Accelerated telomere shortening in glycosylphosphatidylinositol (GPI)-negative compared with GPI-positive granulocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) detected by proaerolysin flow-FISH. Blood 106: 531–533.
Schrader, A. et al. 2018. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat. Commun. 9: 697.
Werner, B. et al. 2015. Reconstructing the in vivo dynamics of hematopoietic stem cells from telomere length distributions. eLife 4: e08687.
Beier, F. et al. 2015. Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide. Leuk. Res. 39: 1292–1298.
Brummendorf, T.H. et al. 2001. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood 97: 895–900.
Ventura Ferreira, M.S. et al. 2017. Evidence for a pre-existing telomere deficit in non-clonal hematopoietic stem cells in patients with acute myeloid leukemia. Ann. Hematol. 96: 1457–1461.
Wenn, K. et al. 2015. Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib. Leukemia 29: 2402–2404.
Cawthon, R.M. 2009. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res. 37: e21.
Gutierrez-Rodrigues, F. et al. 2014. Direct comparison of flow-FISH and qPCR as diagnostic tests for telomere length measurement in humans. PLoS One 9: e113747.
Khincha, P.P. et al. 2017. Correlation of leukocyte telomere length measurement methods in patients with dyskeratosis congenita and in their unaffected relatives. Int. J. Mol. Sci. 18: 1765.
Behrens, Y.L. et al. 2017. Comparison of different methods for telomere length measurement in whole blood and blood cell subsets: recommendations for telomere length measurement in hematological diseases. Genes Chromosomes Cancer 56: 700–708.
Wand, T. et al. 2016. Telomere content measurement in human hematopoietic cells: comparative analysis of qPCR and flow-FISH techniques. Cytometry A 89: 914–921.
Gadalla, S.M. et al. 2016. The limitations of qPCR telomere length measurement in diagnosing dyskeratosis congenita. Mol. Genet. Genomic Med. 4: 475–479.
Lai, T.P., W.E. Wright & J.W. Shay. 2018. Comparison of telomere length measurement methods. Philos. Trans. R. Soc. Lond. B Biol. Sci. 373: 20160451.
Montpetit, A.J. et al. 2014. Telomere length: a review of methods for measurement. Nurs. Res. 63: 289–299.
Aubert, G., M. Hills & P.M. Lansdorp. 2012. Telomere length measurement-caveats and a critical assessment of the available technologies and tools. Mutat. Res. 730: 59–67.
Wang, F. et al. 2013. Robust measurement of telomere length in single cells. Proc. Natl. Acad. Sci. USA 110: E1906–E1912.
Alter, B.P. et al. 2007. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 110: 1439–1447.
Alter, B.P. et al. 2012. Telomere length is associated with disease severity and declines with age in dyskeratosis congenita. Haematologica 97: 353–359.
Alter, B.P. 2007. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. Hematology Am. Soc. Hematol. Educ. Program 2007: 29–39.
Dokal, I. et al. 2015. Clinical utility gene card for: dyskeratosis congenita—update 2015. Eur. J. Hum. Genet. 23: 558–558.
Roy, S. et al. 2018. Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: a Joint Recommendation of the Association for Molecular Pathology and the College of American Pathologists. J. Mol. Diagn. 20: 4–27.
